Meanwhile BTIG lowered the firm’s price target on Humacyte (HUMA) to $8 from $10 and keeps a Buy rating on the shares post the Q4 report. The firm cites the company’s increased share count for ...

Buyers at this edition of the fair appear drawn to works of complexity and institutional resonance. Don't mistake muted demand for collector hesitancy in this dynamic market. On Wednesday, Art Basel ...